23-01-2023 Comments (0)Print
14-01-2023
16-12-2022
29-11-2022
23-01-2023
23-01-2023
18-01-2023
A French biotech company claiming to have the first drug that treats the root cause of type 2 diabetes has completed a Series A funding round.
AdipoPharma expects to enter clinical trials later this year with its drug, PATAS, which treats insulin resistance rather than the symptoms of type 2 diabetes, as most medicines for the disease do.
“The first drug specifically targeting insulin resistance in adipocytes”Newton Biocapital II, a venture capital…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
AdipoPharmaBusiness FinancingDiabetesEndocrinologyFocus OnFranceNewton BiocapitalOne to Watch CompaniesPATASPharmaceuticalResearch
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.
The Pharma Letter
39 to 43 Putney High Street
Putney
London
SW15 1SP
For trial and subscription enquiries please email [email protected]
For editorial enquiries, press releases and events please email [email protected]
For all other queries please email [email protected]
Agile web development by Byte9
Back to top